Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print Created with Sketch. YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Please Log In/Join Now first, and then use this function!

divider

Neoadjuvant and adjuvant breast cancer studies available for your patients

Consider referring your newly diagnosed breast cancer patients to a clinical trial evaluating investigational drug(s) in combination with standard of care.

Although less than 1% of all breast cancers are diagnosed in men worldwide,(2) men may also be eligible for a breast cancer clinical trial.

Although less than 1% of all breast cancers are diagnosed in men worldwide,(2) men may also be eligible for a breast cancer clinical trial.



Breast cancer clinical trials are currently researching the use of investigational drugs for those with unmet needs

  • Cancer cells develop mechanisms to evade immune detection, which can result in tumor progression.
  • Checkpoint inhibition targets regulatory pathways of the immune system and in this study we are investigating whether it has the potential to reduce self-tolerance and enhance anti-tumor immune responses.
  • Data from clinical studies3-6 may support the addition of immuno-oncology drugs to improve outcomes in patients with breast cancer.
Bristol Myers Squibb promotes health equity and seeks to improve the health outcomes of populations disproportionately affected by serious diseases. We are committed to reaching these underserved communities - regardless of race, nationality, or heritage - through our clinical trial programs.



Consider the subtype first, then discuss active clinical trials with your patients

Identify patients based on histological and molecular profiles

Review the importance of primary breast cancer subtypes when discussing trial eligibility with your patients (including men):

ER+/HER2- BREAST CANCER (estrogen receptor positive - sometimes referred to as HR+ or Hormone Receptor positive / human epidermal growth factor receptor 2-positive)

This is a subtype of breast cancer that cancer cells test positive for a receptor proteins that bind to estrogen (ER) and test negative for a protein called human epidermal growth factor receptor 2 (HER2). This subtype of breast cancer is sensitive to treatment with anti-estrogen hormone (endocrine) therapies.

HER2+ BREAST CANCER (human epidermal growth factor receptor 2-positive)

This is a subtype of breast cancer that cancer cells test positive for HER2. This protein promotes the growth of cancer cells. HER2-positive breast cancers tend to be aggressive and are sensitive to HER2-directed therapies.

TRIPLE-NEGATIVE BREAST CANCER (ER-, PR-, HER2-)

This is a subtype of breast cancer that cancer cells test negative for ER, a receptor protein that binds to progesterone (PR) and HER2. This subtype of breast cancer tends to grow and spread faster than other types of breast cancers and are not sensitive to endocrine therapies and HER2-directed therapies.



ER+/HER2- Breast Cancer is associated with good prognosis when diagnosed early and treated appropriately, however recurrences and an increased risk of death persist over time.(7)

Your insights help patients understand their options

An open dialogue with your patients may give them a better understanding of clinical trials. By starting a conversation based on your expert guidance, patients gain the knowledge to confidently make choices regarding the next step in their care. 

Based on survey results from 200 practitioners, 87% of oncologists believe clinical trials provide high-quality care.8



How to refer your patients

Find a trial and a recruiting physician to refer your patient

When referring a patient to a study, please be assured that you will continue to provide primary care for the patient. Study staff will provide study-related care only. 



Connect eligible patients with appropriate trials

If you have a patient you think may qualify for a clinical trial, you can discuss patient eligibility by referring them to a principal investigator.

IMPORTANT STEPS TO SUCCESSFUL PATIENT REFERRALS

 

STEP 1:  REVIEW THE PROTOCOLS and DETERMINE ELIGIBILITY

Review trial details , including key inclusion/exclusion criteria, by clicking on “View Trial Details” below to determine the best trial for your patient.

 

STEP 2:  TALK TO YOUR PATIENT

If you find a trial that your patient might qualify for, talk to them about clinical trial participation.

 

STEP 3:  FIND A RECRUITING SITE

Select a convenient site location from a list of participating clinical trial sites.

 

STEP 4:  MAKE CONTACT

Call the principal investigator to discuss eligibility and enrollment for your patient.

Now enrolling: BMS clinical trials in ER+/HER2- primary breast cancer

Click the links below to review complete eligibility criteria, study site locations, and contact information for these studies.

There are no results found.
Our vision is to discover, develop, and deliver transformational medicines for patients through our internal discovery efforts and innovative collaborations.



divider

References:

  1. AACR Publications/Cancer Research/Abstract 4191: The Worldwide female breast cancer incidence and survival, 2018; Zoubida Zaidi and Hussain Adlane Dib; DOI: 10.1158/1538-7445. AM2019-4191. Published July 2019.
  2. ABC Global Alliance. Breast cancer worldwide. Available at: https://www.abcglobalalliance.org/articles/breast-cancer-worldwide/. Accessed February 24, 2020.
  3. Schmid P, Park YH, Muñoz-Couselo E, et al. Pembrolizumab (Pembro) + chemotherapy (Chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2017;35(suppl_15):556-6.
  4. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. The New England Journal of Medicine. 2018;379;2108-21.
  5. Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY2. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2017;35(suppl_15):506.
  6. Loibl S, Untch M, Burchardi N, et al. Randomized Phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2018;36(15_suppl):104.
  7. Pennisi A, Kieber-Emmons T, Makhoul I, Hutchins L. Relevance of pathological complete response after neoadjuvant therapy for breast cancer. Breast Cancer: Basic and Clinical Research. 2016;10:103-6.
  8. Somkin CP, Altschuler A, Ackerson L, et al. Organizational barriers to physician participation in cancer clinical trials. Am J Manag Care. 2005;11:413-421.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com